| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9979581 | The Journal of Thoracic and Cardiovascular Surgery | 2005 | 8 Pages |
Abstract
Inhibition of cyclooxygenase-2 with low-dose celecoxib restricted the growth of lung cancer in this model. This might be mediated by prostaglandin E2. Higher doses of celecoxib afforded no additional benefit. Chronic therapy with low-dose cyclooxygenase-2 inhibition has the potential to influence tumor progression in non-small cell lung cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Eric M. MD, Robert D. MD, Leah M. MD, Yuanguang MD, Margaret BA, Roberto BS, Vaughn A. MD, Ross. M. MD, PhD,